We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Effect of Gemcitabine on Cell Cycle Arrest and microRNA Signatures in Pancreatic Cancer Cells.
- Authors
DAISUKE NAMIMA; SHINTARO FUJIHARA; HISAKAZU IWAMA; KOJI FUJITA; TAKANORI MATSUI; MAI NAKAHARA; MEGUMI OKAMURA; MASAHIRO HIRATA; TOSHIAKI KONO; NAOKI FUJITA; HIROKI YAMANA; KIYOHITO KATO; HIDEKI KAMADA; ASAHIRO MORISHITA; HIDEKI KOBARA; KUNIHIKO TSUTSUI; TSUTOMU MASAKI
- Abstract
Background/Aim: Gemcitabine, an inhibitor of DNA synthesis, is the gold standard chemotherapeutic agent for pancreatic ductal adenocarcinoma (PDAC). MicroRNAs (miRNAs) play critical roles in cancers, including PDAC. However, less is known about the effect of gemcitabine on PDAC cells and miRNA expression in PDAC. We evaluated the effect of gemcitabine on the cell cycle of PDAC cells in vitro and in vivo and on the miRNA expression profile. Materials and Methods: Effects of gemcitabine on PK-1 and PK-9 cell growth were evaluated using a cell counting kit-8 assay. Xenografted mouse models were used to assess gemcitabine effects in vivo. Results: Gemcitabine inhibited the proliferation and tumour growth of PK-1 cells, and induced S phase cell cycle arrest. Numerous miRNAs were altered upon gemcitabine treatment of PK-1 cells and xenograft models. Conclusion: Altered miRNAs may serve as potential therapeutic targets for improving the efficacy of gemcitabine in PDAC.
- Subjects
PANCREATIC cancer treatment; CANCER chemotherapy; DNA synthesis; PANCREATIC cancer genetics; MICRORNA; HUMAN cell cycle; XENOGRAFTS
- Publication
In Vivo, 2020, Vol 34, Issue 6, p3195
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.12155